Know Cancer

or
forgot password

Determining the Extent and Grade of Prostate Cancer Using MR Elastography, Diffusion Weighted Imaging, and Dynamic Contrast Enhanced MRI With Gadofosveset


Phase 2
18 Years
N/A
Open (Enrolling)
Male
Prostate Cancer

Thank you

Trial Information

Determining the Extent and Grade of Prostate Cancer Using MR Elastography, Diffusion Weighted Imaging, and Dynamic Contrast Enhanced MRI With Gadofosveset


Inclusion Criteria:



- male patients diagnosed with T1C or T2 prostate cancer, awaiting prostatectomy

Exclusion Criteria:

- unable to give informed consent

- contraindication to MRI or MRI contrast agent

- claustrophobia

- renal impairment

- prior hormonal or radiation therapy for prostate cancer

- active prostatitis

- moderate to severe rectal inflammation

- previous rectal surgery

- prostate biopsy within 4 weeks of planned MRI

Type of Study:

Interventional

Study Design:

Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic

Outcome Measure:

Correlation coefficient

Outcome Description:

Correlation coefficient between the expected location and grade of prostate cancer as determined by each new MRI method compared with whole mount histological specimen using a 5 mm grid for spatial reference.

Outcome Time Frame:

This outcome measure will be assessed approximately 4 weeks following prostatectomy (an average of 8 weeks from time of enrolment).

Safety Issue:

No

Principal Investigator

Masoom A Haider, M.D.

Investigator Role:

Principal Investigator

Investigator Affiliation:

Sunnybrook Health Sciences Centre, University of Toronto

Authority:

Canada: Health Canada

Study ID:

334-2011

NCT ID:

NCT01761812

Start Date:

September 2012

Completion Date:

July 2013

Related Keywords:

  • Prostate Cancer
  • Prostate cancer
  • MRI
  • Elastography
  • Gadofosveset
  • Prostatic Neoplasms

Name

Location